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As you read this the seasonal festivities of 2017 will be behind us. Yet since this is the first 
IJPP issue of 2018 it behoves me once again to wish all out authors, readers and reviewers a 
prosperous New Year. I hope it will be productive one for us all as we seek to secure funding 
to conduct rigourous research that will generate evidence to inform better patient care. 
Alternatively you may of course be focusing on methodological developments relevant to 
improving the health services research we undertake,   or looking for new approaches  to 
answer your research question.  In turn of course here at IJPP we hope that this research will 
translate into strong papers that you will submit to IJPP for consideration! Looking forward 
to 2018, a topic of current relevance to researchers, policy makers and even politicians is Big 
Data. Can we use Big Data to answer previously unanswerable questions or to answer 
questions more quickly?  
 
So what do we mean by Big Data? Data has been described by the three Vs (1) of volume 
(the scale and size of data), velocity (the speed at which is generated), and variety (the 
varying forms of data such as both images and text). Conversely  it has been said that there is 
in fact no universal agreement on a single definition of big data although the RCPE (2) has 
posited that traditionally it refers to the large volume of data generated by the electronic 
devices the majority of us use in daily life but it also consists of the increasing volumes of 
data generated when we attend for health or social care. In the UK for example, every time 
you visit a family doctor, receive a prescription, or attend hospital a little bit more 
digital  information is recorded. The potential to link this data to other data about you such as 
your shopping habits, your travels  or your lifestyle suggests infinite possibilities for 
understanding both the development and management of disease.  
 
Understanding how this data can be used in research requires consideration not only of its 
potential but also its limitations, and of the governance arrangements  needed to ensure its 
appropriate use. Data security is a big concern, and it needs only a quick scan of the news 
archives to find reports of datasets being hacked and individual details being accessed by a 
third party (3). These events are increasing each year as the return for the criminal hacker 
gets ever greater. Nonetheless because the convenience of the digital world is now a feature 
of most people’s life, both personal and professional, there is no suggestion that our 
enthusiasm for taking advantage of the digital world is decreasing.  What does this mean for 
health and health services research?  
Firstly we must remember that every piece of data we deal with comes from an individual 
who may also be a patient  and we need to treat that data with confidentiality and respect. 
Even anonymised data can sometimes be liked to an individual because of unusual 
combinations of individual data items- for example a person in a particular age group with a 
rare disease  from an identifiable geographical area. There is much debate about who actually 
owns the data and who is responsible for its use. In health there is an argument that the 
patient themselves owns the data, some believe it is the health care professional eg the 
general practitioner who collected the data and some think it is the NHS/Secretary of State 
for Health. It is also unclear if the owner of the data is accountable for its use. So in the 
previous examples as the data set builds there are multiple owners at different levels. For 
example whilst the patient might own their own dataline, they don’t own the whole data set 
whether this be the pharmacist’s record of dispensed prescriptions or the GP practice 
electronic patient record system. Clearly the pharmacist and GP respectively have a 
responsibility for ensuring these collated datasets are securely stored and access is limited to 
those with a justified need. Likewise once the pharmacy and GP and other records may be 
collated at national levels, owner ship or custodianship passes on. A systematic review (4) 
suggested that health care professionals were in general positive towards data sharing for 
public health purposes.  Barriers identified were concerns about costs, governance and 
interference with the professional-patient relationship. These were built on in subsequent 
empirical work which showed   conditional support for data linkage for enhanced 
pharmacovigilance contingent on adequate anonymization of the data,  ethical approval for 
use and  adherence to legislation and professional codes of conduct (5). None of this is 
surprising but operationalizing it still requires thought. It is also important to understand 
patient views. Whilst many are happy to post intimate details on social media sites and to 
engage in financial transactions there is a perceived concern about similar actions with health 
data. Nonetheless research has confirmed that as with health care professionals patients 
would be willing for their health records to be shared for pharmacovigilance research as long 
as certain conditions were in place including again reassurance on confidentiality controlled 
access and appropriate public engagement to ensure full understanding by the population. (6; 
personal communication). 
To some extent some of the above are already in place to varying degrees in different 
countries. For example in England there is legislation in place for the use of data (Care Act 
2014) whereas in Scotland there is a more pragmatic approach (2). The Wellcome Trust lead  
an initiative ‘Understanding Patient Data' – which aims to support better conversations about 
the use of patient health information, and within this there is a  stream of work exploring the 
implications of new and emerging data-driven technologies for healthcare and research, 
particularly in relation to ensuring public confidence.  The ABPI have published a report 
summarizing the challenges and opportunities of big data and emphasizing the need for 
increased awareness and building capacity and capability (7). However much remains for us 
as researchers to take forward especially thinking of medicines and pharmacy related issues. 
In practical terms  what are the sources of pharmacy data that could be linked to other health 
data, and what research questions could this linked dataset address? How can pharmacy staff 
be engaged to ensure their data is complete and valid? Can pharmacy staff be data literate and 
reassure the public that their data is secure and used in accordance with both the law and 
current ethical standards? These and other aspects of big data will provide our research 
community with much food for thought in the coming months and I look forward to hearing 
your views and seeing your research as we work together to maximise the benefits  and 
minimise the concerns about big data.  
. 
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